Compositions for delivery of drug combinations
OwnerPaul Tardi, Troy Harasym +2inventors
InventorsPaul Tardi, Troy Harasym, Murray Webb, Clifford Shew
Life of this patent
Estimating the term…
Abstract
Compositions which comprise delivery vehicles having stably associated therewith non-antagonistic combinations of two or more agents, such as antineoplastic agents, are useful in achieving non-antagonistic effects when combinations of drugs are administered.
Claims55
A composition which comprises delivery vehicles, said delivery vehicles having stably associated therewith at least a first therapeutic agent and a second therapeutic agent in a mole ratio of the first agent to the second agent which exhibits a non-antagonistic biologic effect to relevant cells in culture or a cell-free system over at least 5% of such concentration range where >1% of the cells are affected (fa>0.01) in an in vitro assay for biologic effect.
A composition which comprises delivery vehicles, said delivery vehicles having stably associated therewith at least a first therapeutic agent and a second therapeutic agent in a mole ratio of the first agent to the second agent which exhibits a non-antagonistic cytotoxic or cytostatic or biologic effect to relevant cells wherein said agents are antineoplastic agents.
A method to prepare a composition comprising delivery vehicles, said vehicles having stably associated therewith at least a first therapeutic agent and a second therapeutic agent in a mole ratio which is non-antagonistic, which method comprises
- a) determining in a relevant cell culture assay or cell-free assay for biological activity a mole ratio of said first and second agent which is non-antagonistic over at least 5% of the concentration range over which greater than 1% of cells are affected (f, >0.01) by said ratio of agents, and
- b) encapsulating with said delivery vehicles a mole ratio of agents determined to be non-antagonistic in step a).
A method to prepare a composition comprising drug delivery vehicles, said vehicles having stably associated therewith at least a first therapeutic agent and a second therapeutic agent in a mole ratio which is non-antagonistic, which method comprises
- a) determining in a relevant cell culture assay or cell-free assay a mole ratio of said first and second agent which is non-antagonistic, wherein said agents are antineoplastic agents and
- b) encapsulating with said delivery vehicles a mole ratio of agents determined to be non-antagonistic in step a).
A method to treat a disease condition in a subject which method comprises administering to a subject in need of such treatment a therapeutically effective amount of a first composition comprising delivery vehicles stably associated with at least a first therapeutic agent and a second composition comprising delivery vehicles stably associated with at least a second therapeutic agent,
- wherein the delivery vehicles in said first and second composition are coordinated with respect to pharmacokinetics;
- and
- wherein said administering is at a ratio of first therapeutic agent to second therapeutic agent that is non-antagonistic.
A kit for treatment of a subject which kit comprises
- in a first container a composition comprising delivery vehicles stably associated with at least one first therapeutic agent;
- in a second container a second composition comprising delivery vehicles stably associated with at least a second therapeutic agent;
- wherein the delivery vehicles in said first and second compositions are coordinated with respect to pharmacokinetic behavior;
- and
- wherein said kit further contains instructions for administering said first and second composition at ratios of said first and second therapeutic agent that are non-antagonistic and/or wherein the amounts of said first and second compositions in said containers is proportional to a ratio of said first and second therapeutic agent that is non-antagonistic and/or said containers are calibrated to dispense amounts of said first and second composition wherein the ratio of first and second therapeutic agents is non-antagonistic.
Dependencies are inferred from the claim text.